期刊
JOURNAL OF GYNECOLOGIC ONCOLOGY
卷 32, 期 2, 页码 -出版社
KOREAN SOC GYNECOLOGY ONCOLOGY & COLPOSCOPY
DOI: 10.3802/jgo.2021.32.e31
关键词
Ovarian Neoplasms; Bevacizumab; Poly(ADP-ribose) Polymerase Inhibitors; Immunotherapy Recurrence
This study aims to investigate if the addition of pembrolizumab and bevacizumab to olaparib maintenance can improve progression-free survival in BRCA wild-type patients with platinum-sensitive recurrent ovarian cancer.
Background: The optimal treatment of BRCA wild-type patients with platinum-sensitive recurrent ovarian cancer remains unknown. Recently, there is an increase in the evidence to support the role of the combination of a poly(adenosine diphosphate-ribose) polymerase inhibitor, anti-angiogenic agents, and immunotherapy as maintenance therapy in BRCA wild-type patients with platinum-sensitive recurrence. We hypothesized that adding pembrolizumab and bevacizumab to olaparib maintenance can increase progression-free survival (PFS) in BRCA wild-type patients with platinum-sensitive recurrent ovarian cancer. Methods: BRCA wild-type patients who received two previous courses of platinum-containing therapy, achieved complete or partial response to last treatment, and the treatment-free interval is >6 months after the penultimate platinum-based chemotherapy offered olaparib maintenance with pembrolizumab and bevacizumab. Forty-four patients will be included from 4 sites across Singapore and Korea. The primary endpoint of the study is 6-month PFS rate.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据